Delivery Order SPE2DB20D2001-SPE2DB25FPNRW
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $5,582.67 to AmerisourceBergen Drug Corp for Trelegy Ellipta 100-62.5-25, a combination inhalation powder medication used to treat chronic obstructive pulmonary disease. This competitively awarded, firm fixed-price delivery order is set to be completed by August 26, 2025, just one day after the award date of August 25, 2025. The pharmaceutical will be delivered to Conshohocken, Pennsylvania, the location of AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $34,728.79 to AmerisourceBergen Drug Corp for the supply of Trelegy Ellipta 100-62.5-25, a combination inhalation powder medication used primarily for chronic obstructive pulmonary disease management. This firm fixed-price delivery order, with an ultimate completion date of August 21, 2025, was awarded on August 20, 2025, through competitive procedures with no set-aside designation. The contract is being performed at...
- The Defense Logistics Agency awarded a $23,885.70 delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Trelegy Ellipta 100-62.5-25, a combination inhalation powder used to treat chronic obstructive pulmonary disease. This non-set-aside contract utilizes firm fixed pricing and is scheduled for completion by August 8, 2025, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. The delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,148.24 to AmerisourceBergen Drug Corp on August 29, 2025, for Trelegy Ellipta 100-62.5-25, a combination inhalation powder medication used to treat chronic obstructive pulmonary disease. The contract is a firm fixed-price delivery order with no set-aside designation, representing a competitive award to the prime contractor. The pharmaceutical product will be delivered to the company's location in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a $10,713.15 delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of TRELEGY ELLIPTA 100-62.5-25 (a combination inhalation powder medication for chronic obstructive pulmonary disease) in a 60-dose package. This competitively awarded, firm fixed price delivery order is scheduled for completion by September 9, 2025, and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,290.36 to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 100-62.5-25, a combination inhalation powder used to treat chronic obstructive pulmonary disease (COPD). The contract is firm fixed price with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of August 5, 2025. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $14,019.75 to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 200-62.5-25, a combination inhalation powder medication used in the treatment of chronic obstructive pulmonary disease. This competitively awarded, firm fixed-price delivery order was issued on August 21, 2025, with an ultimate completion date of August 22, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $3,850.74 to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 100-62.5-25, a combination inhalation powder medication used in the treatment of chronic obstructive pulmonary disease. This competitively awarded, firm fixed-price delivery order was issued on July 31, 2025, with an ultimate completion date of August 1, 2025, and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,154.61 to AmerisourceBergen Drug Corp for Trelegy Ellipta 200-62.5-25 inhalers (60-count units). This competitively awarded, firm fixed-price delivery order was issued on August 19, 2025, with an ultimate completion date of August 20, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a delivery order valued at $4,665.23 to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Trelegy Ellipta 100-62.5-25, a combination inhalation powder used in the treatment of chronic obstructive pulmonary disease. This non-competitive delivery order represents a firm fixed price transaction with a completion date of August 12, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This...
- SPE2DB20D2001Indefinite Delivery Contract
- SPE2DB20D2001-SPE2DB25FPNRWDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $25,599.58 to AmerisourceBergen Drug Corp for the supply of Trelegy Ellipta 100-62.5-25, a combination inhalation powder medication used to treat chronic obstructive pulmonary disease. The contract, awarded on September 10, 2025, with an ultimate completion date of September 11, 2025, represents a firm fixed price delivery order under a competitive procurement with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is fulfilling this order as a child delivery order under its larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion comprehensive pharmaceutical support vehicle running through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving federal medical procurement needs, particularly for military and veteran healthcare systems. This delivery order is typical of the company's extensive federal contracting portfolio with the DLA, which encompasses a wide range of brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. The company's competitive awards reflect its capability to meet rigorous federal procurement requirements and support critical healthcare operations across the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $25.6k | 9/10/25 |